Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients

Table 1 Comparison of clinical baseline data

Factor	Group A, n = 33	Group B, n = 37	P value
Age in yr
≥ 60	13	17	0.580
< 60	20	20
Sex
Male	22	35	0.447
Female	11	12
Course of disease in yr
≥ 5	19	20	0.767
< 5	14	17
BMI in kg/m2
≥ 30	25	30	0.587
< 30	8	7
History of hypertension
Yes	8	10	0.790
No	25	27
History of smoking
Yes	22	35	0.447
No	11	12

BMI: Body mass index.

Table 2 Statistics of adverse reactions

Group	Nausea	Vomiting	Diarrhea	Total incidence
Group A, n = 33	1 (3.03%)	1 (3.03%)	0 (0.00%)	2 (6.06)
Group B, n = 37	4 (10.80%)	3 (8.10%)	2 (5.40)	9 (24.30)
χ2 value				4.393
P value				0.036

Table 3 Change in body mass index

Group	BMI in kg/m2		t value	P value
	Before treatment	After treatment
Group A, n = 33	33.29 ± 4.05	26.89 ± 1.59	8.096	< 0.001
Group B, n = 37	33.35 ± 3.29	30.22 ± 1.48	5.099	< 0.001
t value	0.125	8.999
P value	0.900	< 0.001

BMI: Body mass index.